# Delaware Clinical and Translational Research ACCEL Program

> **NIH NIH U54** · UNIVERSITY OF DELAWARE · 2023 · $209,109

## Abstract

ABSTRACT- OVERALL
This proposal is a competitive renewal of the Institutional Development Award Program Infrastructure for
Clinical and Translational Research (IDeA-CTR)(U54) grant originally awarded in September 2013 to the
University of Delaware. The ACCEL CTR Program, has completed nine years of funding at the time of
this application. During our third funding cycle (ACCEL3), our consortium will consist of four partners:
University of Delaware (UD)—the lead institution; Nemours Children’s Health (Nemours); Christiana
Care Health System (CCHS), the largest health care system in Delaware; and Delaware State University
(DSU), an American historically Black, public university that joined our consortium during the last
competitive renewal. Over the past nine years, ACCEL has established an exceedingly strong network
and infrastructure for clinical and translational (C&T) research within the state of Delaware; and, we are
now poised and ready to continue our growth trajectory. While we will continue with the activities that
have made us successful, we will have a sharper focus on building sustainable infrastructure across
the state that can continue to thrive and mature for years to come. And, we will focus on creating a
scientific culture focused, not only, on improving the health of Delawareans, but doing so through a lens
of health equity. In our mission to establish a cadre of successful C&T scientists in DE, we will use
various approaches to promote full consideration of how their work impacts the needs of all members of
society, from design to study implementation to dissemination of findings. And, we will have a much
greater focus on building a bi-directional relationship between our scientists and the community so that
we can have a greater impact on Delawareans. Delaware is an ideal state for a CTR grant as it
represents the whole of the USA in a compact form. The population of Delaware (~970,000) mirrors the
US population in urban-to-rural citizen ratio and ethnic/racial diversity, with 23% African American, 62%
Caucasian, 10% Hispanic, 4% Asian and 1% Native American. Thus, studies involving a cross-section of
Delaware can be generalizable to populations nationally. The dominance of adult (CCHS) and pediatric
(Nemours) hospital systems, which serve at least 85% of the residents of the state, provides a unique
opportunity to treat the state of Delaware as a model for examining how healthcare changes can impact
population health. The overarching goal of the ACCEL CTR Program is to create a unified Delaware
Clinical and Translational Research Community (inclusive of investigators and community members) that
breaks down existing barriers, capitalizes on the unique strengths of its partners to establish
infrastructure and accelerates the creation of equitable solutions that improve the health of all
Delawareans and all Americans.

## Key facts

- **NIH application ID:** 10885455
- **Project number:** 3U54GM104941-11S2
- **Recipient organization:** UNIVERSITY OF DELAWARE
- **Principal Investigator:** Gregory E Hicks
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $209,109
- **Award type:** 3
- **Project period:** 2013-09-25 → 2028-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10885455

## Citation

> US National Institutes of Health, RePORTER application 10885455, Delaware Clinical and Translational Research ACCEL Program (3U54GM104941-11S2). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10885455. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*